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ABSTRACT 
Purpose: To evaluate the reproducibility of semi-quantitative parameters obtained from 
two FDG-PET studies using two different PET scanners.  Methods: Forty-five patients 
underwent FDG-PET examination with two different PET scanners on separate days.  
Two PET images with different attenuation correction method were generated in each 
patient and three ROIs were placed on the lung tumor and normal organs (mediastinum 
and liver) in each image.  Mean and maximum SUVs, tumor-to-mediastinum and 
tumor-to-liver ratios (T/M and T/L) and the percentage difference in parameters 
between 2 PET images (% Diff.) were compared.  Results: All measured values except 
maximum SUV in the liver and tumor-related parameters (SUV in lung tumor, T/M, 
T/L) showed no significant difference between 2 PET images.  Conclusion: The mean 
measured values showed high reproducibility and demonstrate that follow-up study or 
measurement of tumor response to anticancer drugs can be undertaken by FDG-PET 
examination without specifying the particular type of PET scanner. 
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INTRODUCTION 
Positron emission tomography (PET) using 2-deoxy-2-[18F]fluoro-D-glucose 
(FDG) is an established diagnostic tool for oncological imaging [1].  The role of PET 
imaging in clinical oncology and patient care has been expanding; however, PET has 
poor spatial resolution compared to other conventional morphologic modalities such as 
CT and MR, and the lack of anatomical landmarks can make the interpretation of PET 
images difficult.  To overcome this problem, several approaches have been evaluated 
to fuse functional PET images with anatomical images [2], mainly for imaging of the 
brain and the head and neck [3-5].  The advent of scanners that combine PET and CT 
has enabled the acquisition of co-registered anatomical and functional images in a single 
scanning session; the PET/CT images are used both for diagnosing and staging disease 
and for evaluating the response to therapy [6,7]. 
Recently, it has become the norm for an institution to have multiple PET scanners; 
sometimes both PET and PET/CT are placed in the same institution.  In evaluating 
lesions using PET, semi-quantitative parameters such as standardized uptake value 
(SUV) are commonly applied.  In the assessment of therapies using quantitative 
parameters in PET, reproducibility of the parameters is critically important.  SUV is 
defined as tissue concentration (MBq/mL) divided by activity injected per body weight 
(MBq/kg); many authors have discussed multiple factors that affect SUV, such as 
weight, plasma glucose level, length of uptake period, partial-volume effects, and 
recovery coefficient [8-12]. 
Previous studies have expressed concern about the reproducibility of measured 
values using FDG-PET.  Two factors affect the difference between two measured 
values: one arising from the type of attenuation correction method (CT vs. 
Germanium-68 or CT tube current) [13-15], and the other from the examination interval 
[16-19].  Previous reports have evaluated these two factors separately: there are no 
reports that account for them simultaneously. 
In the future, different PET scanners will be used for follow-up studies and 
measurement of tumor response to treatment in the clinical situation.  Before this 
occurs, it is important to determine whether it is appropriate to use different types of 
PET scanners interchangeably within the same institution. 
In the evaluation of brain lesions, the lesion-to-normal ratio derived from 
FDG-PET image only was used as a semi-quantitative parameter [19] prior to the 
introduction of SUV.  In the present study, we also sought to assess the reproducibility 
of this parameter by applying the mediastinum and liver as reference regions.  The 
purpose of this study is to evaluate the reproducibility of semi-quantitative parameters 
obtained from two FDG-PET studies using two different PET scanners, and to 
determine the appropriate parameters for comparison between the two studies. 
MATERIALS AND METHODS 
Patients 
This study included a total of 45 patients (32 male and 13 female; mean age, 69.5 ± 
9.8 years; age range, 46–89 years) with tumors of the lung, with known or suspected 
malignant lung disease.  All patients underwent FDG-PET examination with two 
different PET scanners in separate days; the examination interval ranged from 1 to 58 
days (mean, 14.6 ±11.5 days).  The tumor size ranged from 8 to 68 mm in diameter 
(mean, 30.2 ± 12.8 mm in diameter).  The order of two scans with two scanners was 
randomized; 15 patients underwent PET/CT first and 30 underwent PET first.  No 
treatment interventions were given to the patients between the two scans.  Written 
informed consent was obtained from all patients participating in this study, which was 
approved by the institutional review board of the University of Fukui Hospital. 
 
Data acquisition 
FDG-PET was performed using both a commercial combined PET/CT scanner 
(Discovery LS, General Electric Medical Systems, Waukesha, WI) and a PET scanner 
(Advance, GE) in all patients.  For both the PET/CT and PET scanners, 35 transaxial 
images were acquired simultaneously per field of view with an interslice spacing of 
4.25 mm.  The PET/CT scanner incorporates an integrated 4-slice multidetector CT 
scanner, which was used for attenuation correction.  CT scanning parameters were as 
follows: Auto mA (upper limit, 40 mA; noise index, 20), 140 kV, 5-mm section 
thickness, 15-mm table feed, and pitch of 4.  For attenuation correction of the PET 
scanner, the 68Ge rod source was used. 
The same acquisition protocol for the emission scan was used in PET/CT and PET 
scanner.  After at least 4 hours fasting, patients received an intravenous injection of 
185 MBq of FDG; image acquisition began 50 min after injection.  A whole-body 
emission scan was performed from the head to the inguinal region with 2 min per bed 
position (7–8 bed positions).  A transmission scan with CT was performed prior to the 
emission scan with PET/CT scanner.  A post-injection transmission scan with 68Ge rod 
source following the emission scan was performed for 1 min per bed position in the 
same area as the emission scan with PET scanner. 
  
Image reconstruction 
For PET/CT, the CT images were created with a matrix size of 512 x 512 before 
being converted to 128 x 128 matrices to correspond to the PET emission images.  For 
PET, segmented attenuation correction (SAC) was used for conventional 68Ge 
correction.  The reconstructed 68Ge transmission map was automatically segmented 
into classes of differing average attenuation and the average attenuation coefficient 
within each class was substituted for the raw pixel-by-pixel values.  These attenuation 
correction factors were then applied to the emission data, and the attenuation-corrected 
emission images were reconstructed with ordered-subset expectation maximization 
(OSEM) iterative reconstruction algorithm (2 iterations, 14 subsets).  Reconstructed 
images were converted to SUV images with the patient’s body weight and injected dose 
of FDG. 
In following the above procedure, two different PET images were produced: one 
representing attenuation correction based on transmission data from the CT (PET/CT 
image), and the other based on transmission data from the 68Ge (PET/Ge image). 
 
Data analysis 
In this study, image co-registration between PET/CT and PET/Ge image was not 
performed.  The closest slice of each image was selected visually and identical regions 
of interests (ROIs) were placed over the same locations.  ROIs were placed on both 
normal organs and lung tumor; for the normal organs, SUVs were measured in the 
mediastinum and liver.  The shape of ROIs was all circular and their diameters were as 
follows: 8 mm for lung tumor, 20 mm for mediastinum, and 60 mm for liver.  Both 
mean (average of all pixels within the ROI) and maximum (hottest single pixel within 
the ROI) SUVs were compared between the two images for each patient.  Mean and 
maximum tumor-to-mediastinum and tumor-to-liver ratios (T/M and T/L, respectively) 
were calculated as image-derived semi-quantitative parameters using the following 
equations: 
Mean T/M (T/L) = mean SUV in lung tumor / mean SUV in mediastinum (liver) 
Maximum T/M (T/L) =  
 maximum SUV in lung tumor / mean SUV in mediastinum (liver). 
 
Statistical analysis 
Results are expressed as mean ± SD.  The differences in individual SUVs 
between the two images were compared using the paired t-test.  p < 0.05 was 
considered significant.  To assess the intrasubject variability of all values including the 
systematic difference between the two scanners and the scan order, the percentage of 
absolute and signed difference (% Diff._abs, sig) of SUVs, T/M, and T/L were 
calculated using the following formula: 
% Diff._abs = |X1 - X2|/Xm×100 
% Diff._sig = (X1 - X2)/Xm×100 
where X1 is SUV, T/M, and T/L in the PET/Ge or second scan image, X2 is SUV, T/M, 
and T/L in the PET/CT or first scan image, and Xm is the mean value of X1 and X2.  In 
addition, to estimate the degree of agreement between two different measured values the 
intraclass correlation coefficient (ICC) was calculated using the following formula: [20] 
ICC = (MSBS – MSWS) / {MSBS + (k-1)MSWS} 
where MSBS and MSWS are the mean sum of squares between and within subjects, 
respectively. The equation for calculating MSBS and MSWS is kσb2+σw2 and σw2.  σb2 
and σw2 is the variance between and within subjects and k is the number of 
within-subject measurements, being 2 in the present study.  The ICC is a coefficient of 
reliability and generalizability that is calculated using variance estimates obtained via an 
analysis of variance; it is considered to be an average correlation across testers.  ICC 
ranges between 0.00 and 1.00; values closer to 1.00 represent stronger reliability.  A 
lower 95% ICC confidence boundary was also calculated to test the statistical 
significance of the observed ICC.  The equation for calculating lower 95% ICC 
confidence boundary is (FL – 1) / (FL + 1) [21].  FL is obtained from the following 
equation with F-test: 
FL = F0/F1-α/2[(n-1), n(k-1)]. 
F0 is MSBS/MSWS, and α, n, k is 0.05, 45, 2 in this study. 
RESULTS 
T/M and T/L values and SUVs are summarized in Table 1 (mean measured values) 
and Table 2 (maximum measured values), along with p-values.  Except for maximum 
SUV in the liver and tumor-related parameters (SUV in lung tumor, T/M, T/L), no 
significant difference was observed between the two images. 
A summary of % Diff. and ICC is provided in Table 3 (for mean measured values) 
and Table 4 (for maximum measured values), along with the 95% confidence interval 
(95% CI).  All mean measured values demonstrated smaller % Diff._abs and better 
ICC compared with maximum measured values.  In mean measured values, mean % 
Diff_sig was less than 5 % although larger % diff_sig between the two scanners were 
observed in SUVmax, T/M(L)max. 
The ICC was significantly positive for all types of measured values, which means 
that ICC was higher than the lower 95% ICC confidence boundary. 
For the evaluation of tumor-related parameters, all patients were divided into two 
groups according to the examination interval and the ICCs of each group were 
compared.  One group underwent the two PET examinations with an interval of more 
than 15 days, while the interval was less than 15 days in the other group.  There was 
good agreement between the groups, as shown in Table 5; the results were significantly 
positive.
DISCUSSION 
In the present study, measured semi-quantitative values obtained by different 
attenuation correction methods and on different days showed significant reliability, 
although significant difference was observed for some parameters.  PET enables direct 
quantification of lesion radioactivity levels as an alternative to measuring tumor size.  
SUV, a semi-quantitative parameter commonly used in PET imaging, is also referred to 
as the dose uptake ratio (DUR), i.e., radioactivity concentration adjusted by body 
weight and injected dose, and its characteristics, significance, and limitations have been 
described in several reports [8,22].  Other reports concern the reproducibility of the 
value measured with FDG-PET.  Two factors affect the difference between the two 
measured values: one arises from differences in the method of attenuation correction, 
the other from the examination interval.  In reports regarding differences between the 
two different attenuation correction methods [13-15], the differences in the measured 
values between CT-corrected images and 68Ge-corrected images were 2.3 % 
(SUVmean) and 2.1% (SUVmax) in non-osseous lesions[13], and 3.0 ± 8.3 % at 20 
MBq/cc of tissue activity in tumorous lesions [14].  Souvatzoglou et al. [15] reported 
that max and mean SUVs measured with PET and PET/CT showed no significant 
difference.  Studies concerned with differences in examination intervals report high 
reproducibility of the measured values; that is, within 1 week to 10 days of the 
examination interval the approximate average percentage difference for cancerous 
lesions was 10% [16-18].  The SUVs measured in normal liver and mediastinum in 
cancer-free patients were stable over time [19]; the % differences of SUVmean and 
SUVmax between the two studies were also approximately 10%.  In these reports, 
the % difference was calculated as either absolute [13,17,18] or signed difference [16].  
As we calculated both absolute and signed difference, we compared our results and 
there reports. 
The results of the present study revealed larger percentage differences for 
measured values compared with the previous studies stated above.  There were two 
factors in our study that might have caused differences in the measured values: (i) 
differences in the attenuation correction methods and examination intervals and the 
additive effect of the percentage difference; and (ii) variation in the study protocol, that 
is, difference in transmission scan duration.  Previous studies reported transmission 
scan durations with 68Ge rod source as 3 [13], 4–5 [17,18], and 15 min [16], which are 
longer than that in the present study.  Visvikis et al [23] reported that a larger 
percentage difference in SUV results from a shorter transmission duration.  This may 
have caused the larger percentage difference in the present study compared with those 
of previous reports. 
In the present study, significant difference in the measured value was observed for 
maximum SUV in the liver and tumor-related parameters.  Nakamoto et al. [13] also 
reported significant difference in the measured value between CT- and 68Ge-corrected 
images in some regions; this difference might arise from the different attenuation 
correction methods.  For patients with lung tumors, significant difference was 
demonstrated only in the group with a longer examination interval (> 15 days; data not 
shown).  This difference might be explained by the effect of tumor growth. 
We also evaluated the reproducibility of the lesion/normal ratio (T/M and T/L) in 
the present study.  This semi-quantitative parameter, which was used for the 
assessment of brain tumors [24] until the advent of SUV and is still in use, is regarded 
as a more reliable method than SUV [25].  In whole-body FDG-PET imaging, SUVs 
measured in normal liver and mediastinum are stable over time [19]; these areas are 
considered to be good reference regions.  In our results, no significant difference was 
observed in mean T/M and T/L between the images of the two different studies, and 
the % Diff._abs and ICC values were comparable to that of SUVs in lung tumor.  
Therefore, it is thought that specifying semi-quantitative parameter will not be required.  
The difference in maximum T/M and T/L between the two images might reflect the 
difference in maximum SUV for lung tumor, as stated above. 
Compared with maximum measured value, the % Diff._abs and ICC for mean 
measured value showed a better trend because it was less affected by statistical noise. 
In the assessment of the systematic difference with % signed difference between 
the two scanners and the scan order, less than 5 % of difference was observed in most 
parameters, except SUVmax_L and T/M(L)max. This means the systematic difference 
does not exist regarding with the scanner and scan order. 
Regarding the clinical implications of this study, the European Organization for 
Research and Treatment of Cancer (EORTC) PET study group recommends that 
reproducibility data for tumor FDG measurement should be collected to assess precisely 
the level of change that can be measured for follow-up study, if the differences in tumor 
measurements performed on conventional PET scanners made with no intervening 
chemotherapy are in the order of 10–20% [11].  In this respect, we consider overall 
that the differences in SUVs measured in our report using two different devices on 
separate days are within the permissible range.  Both PET and PET/CT can be used in 
the clinical situation for follow-up study or measurement of tumor response to 
anticancer drugs, without specifying a particular type of PET scanner for following-up a 
certain patient.  Accounting for the % Diff., ICC, and the significance of the two 
measured values between PET/Ge and PET/CT images, the present study demonstrates 
the high reproducibility of the mean SUV, T/M, and T/L, although the size and shape of 
the ROIs require further consideration. 
In this study, two PET scanner from the same vendor was used.  To extrapolate 
our conclusion to other scanners from different vendors, further examination will be 
required. 
CONCLUSION 
In the present study, we assessed the reproducibility of semi-quantitative measured 
values obtained in two different PET scanners.  The mean measured value and 
lesion/normal ratio showed high reproducibility and demonstrate that follow-up study or 
measurement of tumor response to anticancer drugs can be undertaken by FDG-PET 
examination without specifying the type of PET scanner. 
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TABLE 1 
Mean measured values for PET/Ge and PET/CT 
 PET/Ge PET/CT p 
SUV_T 8.40 ± 4.30 8.22 ± 3.92 0.35 
SUV_M 1.67 ± 0.26 1.73 ± 0.25 0.09 
SUV_L 2.05 ± 0.30 2.06 ± 0.30 0.77 
T/M 5.20 ± 2.89 5.03 ± 2.88 0.20 
T/L 4.24 ± 2.33 4.12 ± 2.16 0.29 
SUV_T (M, L): mean SUV in lung tumor (mediastinum, liver)  
T/M (T/L): lung tumor/mediastinum (/liver) ratio 
  
TABLE 2 
Maximum measured values for PET/Ge and PET/CT 
 PET/Ge PET/CT p 
SUVmax_T 11.0 ± 5.03 10.2 ± 4.61 0.02* 
SUVmax_M 2.15 ± 0.36 2.08 ± 0.28 0.11  
SUVmax_L 2.89 ± 0.46 2.71 ± 0.38 0.004*
T/Mmax 6.43 ± 3.43 5.79 ± 3.37 0.004*
T/Lmax 5.23 ± 2.73 4.87 ± 2.74 0.02* 
 *p < 0.05 
SUVmax_T (M, L): maximum SUV in lung tumor (mediastinum, liver) 
T/M (T/L)max: maximum T/M (T/L) 
 
 TABLE 3 
% Diff. and ICC for mean measured values 
 
 
  % Diff._abs 95% CI ICC 
SUV_T 12.0 ± 10.2 8.93 - 15.2 0.95  
SUV_M 11.2 ± 9.91 7.91 - 13.9 0.52  
SUV_L 8.85 ± 8.22 6.12 - 11.1 0.67  
T/M 11.2 ± 9.91 7.91 - 13.9 0.95  
T/L 14.3 ± 11.4 10.9 - 17.8 0.94  
 
  % Diff_sig(scanner) range % Diff_sig(order) range 
SUV_T 2.47 ± 15.6 -32.9 - 36.2 3.10 ± 15.5 -32.9 - 36.2
SUV_M -3.87 ± 14.5 -38.7 - 29.6 0.10 ± 15.0 -38.7 - 32.2
SUV_L -0.53 ± 12.1 -19.5 - 33.3 0.94 ± 12.1 -19.5 - 33.3
T/M 3.87 ± 14.5 -29.6 - 38.7 -0.72 ± 15.0 -32.2 - 38.7
T/L 2.98 ± 18.1 -37.6 - 49.8 2.17 ± 18.2 -49.8 - 42.8
 
SUV_T (M, L): mean SUV in lung tumor (mediastinum, liver)  
T/M (T/L): lung tumor/mediastinum (/liver) ratio 
% Diff_abs: percentage of absolute difference 
% Diff_sig (scanner): percentage of signed difference between the two scanners 
% Diff_sig (order): percentage of signed difference between the scan order 
 TABLE 4 
% Diff. and ICC for maximum measured values 
 
  % Diff._abs 95% CI ICC 
SUVmax_T 16.1 ± 10.5 13.0 - 19.4 0.93  
SUVmax_M 12.1 ± 9.60 8.86 - 14.2 0.47  
SUVmax_L 13.0 ± 8.13 10.5 - 15.4 0.48  
T/Mmax 19.1 ± 12.3 15.4 - 23.0 0.90  
T/Lmax 17.1 ± 12.0 13.5 - 20.9 0.92  
 
  % Diff_sig(scanner) range % Diff_sig(order) range 
SUVmax_T 0.90 ± 17.0 -21.5 - 49.3 4.82 ± 18.7 -25.0 - 49.3
SUVmax_M 3.26 ± 15.2 -32.7 - 39.6 4.59 ± 14.9 -32.7 - 39.6
SUVmax_L 6.37 ± 14.1 -26.9 - 36.4 2.97 ± 15.2 -24.2 - 36.4
T/Mmax 12.8 ± 18.9 -23.1 - 54.5 4.13 ± 22.6 -54.5 - 50.1
T/Lmax 9.51 ± 18.7 -30.9 - 60.6 3.92 ± 20.7 -60.6 - 37.9
 
SUVmax_T (M, L): maximum SUV in lung tumor (mediastinum, liver)  
T/M (T/L)max: maximum T/M (T/L) 
% Diff_abs: percentage of absolute difference 
% Diff_sig (scanner): percentage of signed difference between the two scanners 
% Diff_sig (order): percentage of signed difference between the scan order 
 
 TABLE 5 
ICC for lung tumor accounting for tumor growth 
 within 15 days over 15 days 
SUV_T 0.96  0.93  
SUVmax_T 0.93  0.93  
   
T/M 0.97  0.93  
T/Mmax 0.88  0.80  
   
T/L 0.94  0.92  
T/Lmax 0.92  0.92  
SUV_T: mean SUV for lung tumor 
SUVmax_T: maximum SUV for lung tumor 
T/M (T/L): lung tumor/mediastinum (/liver) ratio 
T/M (T/L)max: maximum T/M (T/L) 
 
 
 
